Multiple myeloma electrocardiogram

Jump to navigation Jump to search

Multiple myeloma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple Myeloma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Multiple myeloma electrocardiogram On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple myeloma electrocardiogram

All Images
X-rays
Echo and Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple myeloma electrocardiogram

CDC on Multiple myeloma electrocardiogram

Multiple myeloma electrocardiogram in the news

Blogs on Multiple myeloma electrocardiogram

Directions to Hospitals Treating Multiple myeloma

Risk calculators and risk factors for Multiple myeloma electrocardiogram

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Hannan Javed, M.D.[2]; Shyam Patel [3]

Overview

There are two indications for obtaining an electrocardiogram in the workup and management of multiple myeloma: carfilzomib use and evaluation of cardiac amyloidosis. In both of these situations, a baseline electrocardiogram may be useful. Subsequent electrocardiograms may be useful for monitoring. Electrocardiogram abnormalities include atrioventricular block and low voltage QRS complexes.

Electrocardiogram

There are two indications for obtaining an electrocardiogram in the workup and management of multiple myeloma:

References

  1. Chari A, Hajje D (2014). "Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring". BMC Cancer. 14: 915. doi:10.1186/1471-2407-14-915. PMC 4289164. PMID 25471129.
  2. Guan J, Mishra S, Falk RH, Liao R (2012). "Current perspectives on cardiac amyloidosis". Am J Physiol Heart Circ Physiol. 302 (3): H544–52. doi:10.1152/ajpheart.00815.2011. PMC 3353775. PMID 22058156.